Pengxiang Chang obtained his bachelor degree in Veterinary medicine from the Northwest A&F University, China. He started the PhD study in the School of Veterinary Medicine and Science, the University of Nottingham in 2010. His PhD project focused on the host innate immune response to different influenza viruses. Later on, he joined the Faculty of Medicine & Health Sciences, Nottingham to work as a research assistant. He worked on the European project Immodgel to study the immune modulation through surface engineering. Pengxiang joined the Pirbright Institute in 2015 and started to work on the Zoonosis and Emerging Livestock Systems (ZELS) project. One part of the work is on the multivalent influenza vaccine using the CRISPR-Cas9 technology. The other part of the work is on the antigenic characterization of H5 and H7 influenza viruses.